Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Case report

Amrubicin

Anaemia and pneumonitis: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Imai H, et al. Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. Investigational New Drugs 40: 1066-1079, No. 5, Oct 2022. Available from: URL: http://doi.org/10.1007/s10637-022-01269-9 Imai H, et al. Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. Investigational New Drugs 40: 1066-1079, No. 5, Oct 2022. Available from: URL: http://​doi.​org/​10.​1007/​s10637-022-01269-9
Metadaten
Titel
Amrubicin
Anaemia and pneumonitis: 2 case reports
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-25298-7

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Emicizumab